ERCC1

$199.00$523.00

Clear
SKU: 3147 Categories: ,

The excision repair cross-complementation group 1 (ERCC1) gene encodes a protein required for nucleotide excision repair and inter-strand crosslink repair of DNA (1). While DNA-damaging chemotherapeutic drugs like cisplatin are commonly used for non-small cell lung carcinoma and other late-stage tumors, these drugs have a high degree of resistance and severe side effects (1,3). Platinum chemotherapy drug resistance has been linked to elevated levels of ERCC1-XPF nuclease, therefore making ERCC1 a potential predictive diagnostic biomarker (2,3). ERCC1 expression may have prognostic value in lung, colorectal, head and neck, bladder, breast and cervical cancers (1-7).

Although clone 8F1 has traditionally been used in immunohistochemistry to detect ERCC1 expression, 8F1 has been found to cross-react with PCYT1A, an unrelated nuclear membrane protein. Clone 4F9 does not show this cross-reaction, providing superior specificity for ERCC1 expression (2-4).

Intended Use

IVD

Format

Concentrate

Volume

0.1 ml, 0.5 ml

Source

Mouse Monoclonal

Clone

4F9

Isotype

IgG1

Antigen

Protein expressed in 293T cell transfected with human ERCC1 expression vector

Localization

Nuclear, cytoplasmic

Positive Control

Prostate or prostate cancer

1. Bhagwat NR, et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009 Sep 1;69(17):6831-8.
2. Ma D, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. 2012 Nov 21;12:88.
3. Smith DH, et al. Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. Sci Rep. 2014 Mar 7;4:4313.
4. Bauman JE, et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer. 2013 Oct 15;109 (8):2096-105.
5. Ozcan MF, et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol Oncol. 2013 Nov;31(8):1709-15.
6. Palomba G, et al. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med. 2014 Sep 25;12:272.
7. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
8. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.